熊去氧胆酸胶囊对原发性胆汁性肝硬化小鼠肝组织的保护作用被引量：2

Protective effect of Ursodeoxycholic acid on hepatic tissues of primary biliary cirrhosis in rats

下载PDF

导出

摘要目的探讨熊去氧胆酸胶囊对原发性胆汁性肝硬化小鼠肝组织的保护作用。方法 C57BL/6小鼠腹腔注射聚肌胞苷酸建立原发性胆汁性肝硬化模型,观察各组小鼠肝组织超微结构的改变。结果与正常组比较,模型组CK19阳性表达明显,胆管增生活跃,胆小管数量增多,管腔畸形,胶原纤维沉积明显。熊去氧胆酸低剂量组、高剂量组胆小管增生较模型组减少,有少量增生的胶原纤维,CK19表达减弱(P<0.05)。结论熊去氧胆酸对原发性胆汁性肝硬化小鼠的肝组织具有明显的保护作用。 Objective To investigate the protective effect of Ursodeoxycholic acid on liver tissues of primary biliary cirrhosis in rats. Methods The primary biliary cirrhosis model of C57BL/6 mouse which was induced by Polyinosinic- polycytidylic acid （poly I：C） was established. The ultrastructural changes of liver tissues under transmission electron microscope （TEM） were observed. Results Compared with normal group, expression of CK19 was positive obviously, bile canaliculus increased, lumen deformitied and collagen fibers deposited significantly in liver pathology of model group. The low and high Ursodeoxycholic acid groups showed that increased bile canaliculus and proliferation of collagen fiber reduced compared with model group （P 〈 O. 05）. Conclusion Ursodeoxycholic acid has significant protective effect on the hepatic tissues of primary biliary cirrhosis model in mice.

作者郭晓霞李良学武玉鹏刘改萍冯玛莉

机构地区山西省中医院肝病科山西省中医药研究院临床药理实验室山西省中医院病理科

出处《胃肠病学和肝病学杂志》 CAS 2015年第11期1314-1318,共5页 Chinese Journal of Gastroenterology and Hepatology

基金山西省卫生和计划生育委员会科技攻关项目(201301019)

关键词熊去氧胆酸聚肌胞苷酸原发性胆汁性肝硬化肝组织保护作用 Ursodeoxycholic acid Polyinosinie-polycytidylic acid Primary biliary cirrhosis Liver tissue Protective effect

分类号 R575.2 [医药卫生—消化系统]

引文网络
相关文献

参考文献12

1Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis [J].Hepatology, 2009, 50(1) : 291-308.
2Concepcion AR, Medina JF. Approaches to the pathogenesis of primarybiliary cirrhosis through animal models [ J]. Clin Res Hepatol Gastro-enterol, 2012’ 36(1) : 21-28.
3Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed inhuman pulmonary, colonic, and mammary tumors [J]. Cancer, 2000,89(12) : 2637-2645.
4Talwalkar JA, Souto E, Jorgensen RA, et al. Natural history of pruri-tus in primary biliary cirrhosis [J]. Clin Gastroenterol Hepatol, 2003,1(4) : 297-302.
5Hirschfield GM. Diagnosis of primary biliary cirrhosis [ J]. Best PractRes Clin Gastroenterol,2011, 25(6) : 701 -712.
6Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk:A systematic review and meta-analysis [ J ]. Hepatology, 2012,56(4): 1409-1417.
7Zhao DT,Liao HY , Zhang X, et al. Human leucocyte antigen allelesand haplotypes and their associations with antinuclear antibodies fea-tures in Chinese patients with primary biliary cirrhosis [ J]. Liver Int,2014,34(2) : 220-226.
8Working Subgroup ( English version) for Clinical Practice Guidelinesfor Primary Biliary Cirrhosis. Guidelines for the management of primarybiliary cirrhosis : The Intractable Hepatobiliary Disease Study Groupsupported by the Ministry of Health, Labour and Welfare of Japan [ J].Hepatol Res, 2014, 44 ( Suppl 1 ) : 71-90.
9Kohjima M, Enjoji M, Yada R, et al. Pathophysiological analysis of pri-mary biliary cirrhosis focusing on choline/phospholipid metabolism [ J ].Liver Int, 2015, 35(3) : 1095-1102.
10Pouponr R. Ursodeoxycholic acid and bile-acid mimetics as therapeu-tic agents for cholestatic liver diseases: an overview of their mecha-nisms of action [ J]. Clin Res Hepatol Gastroenterol,2012,36 ( Sup-pll) : S3-S12.